VISYNC TECHNOLOGIES, S.A. – Trademark Portfolio
Entity Type: 98
VISYNC TECHNOLOGIES, S.A. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 1 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 4 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include VISYNC.
Av. República, Quinta do Marquês Edifício
Biofarma P-4350-158 Oeiras
Showing of trademarks Trademarks
Trademark Classifications
VISYNC TECHNOLOGIES, S.A.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does VISYNC TECHNOLOGIES, S.A. have?
VISYNC TECHNOLOGIES, S.A. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.
What trademark classes does VISYNC TECHNOLOGIES, S.A. file in?
VISYNC TECHNOLOGIES, S.A. files trademarks across 4 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 10 (Medical Apparatus), Class 44 (Medical Services), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.
What are VISYNC TECHNOLOGIES, S.A.'s most well-known trademarks?
VISYNC TECHNOLOGIES, S.A.'s registered trademark portfolio includes well-known marks such as VISYNC. These are among 1 currently registered trademark in the portfolio.
What is VISYNC TECHNOLOGIES, S.A.'s trademark registration success rate?
VISYNC TECHNOLOGIES, S.A. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.